Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

South Africa’s Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best ...

SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach. A newly ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor designed to inhibit HIV replication at multiple stages of its lifecycle. A New Drug Application (NDA) has been submitted to the ...

SAHPRA has registered Lenacapavir, a new six-monthly PrEP injection to prevent HIV-1 in adults and adolescents over 35 kg.